Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 10/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10457830 | 0.96 | TYMP (0.40) | TYMPKDM4ETAS1R3TAS1R1 | |
| SCHEMBL31635532 | 0.96 | TYMP (0.40) | TYMPKDM4ETAS1R3TAS1R1 | |
| SCHEMBL13838198 | 0.96 | TYMP (0.40) | TYMPKDM4ETAS1R3TAS1R1 | |
| SCHEMBL10459534 | 0.87 | TYMP (0.51) | TYMPKDM4ETAS1R3TAS1R1NT5E | |
| SCHEMBL10460984 | 0.87 | TYMP (0.51) | TYMPKDM4ETAS1R3TAS1R1NT5E | |
| SCHEMBL10461189 | 0.86 | TYMP (0.38) | TYMP | |
| SCHEMBL10457923 | 0.86 | TYMP (0.38) | TYMP | |
| SCHEMBL23138150 | 0.85 | TYMP (0.45) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL668619 | 0.85 | TYMP (0.45) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL30866953 | 0.85 | TYMP (0.44) | TYMPKDM4ETAS1R3TAS1R1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | RNMT, RNGTT, NSUN2 | TYMP 91/4885KDM4E 3200/4885TAS1R3 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.